tiprankstipranks
Trending News
More News >
InnoCan Pharma (TSE:INNO)
:INNO
Advertisement

InnoCan Pharma (INNO) AI Stock Analysis

Compare
19 Followers

Top Page

TSE:INNO

InnoCan Pharma

(OTC:INNO)

Select Model
Select Model
Select Model
Neutral 45 (OpenAI - 4o)
Rating:45Neutral
Price Target:
C$13.00
▼(-33.16% Downside)
InnoCan Pharma's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and negative profitability. Technical analysis shows mixed signals, with no clear trend direction. The valuation is poor due to a negative P/E ratio and lack of dividends, further weighing down the score.

InnoCan Pharma (INNO) vs. iShares MSCI Canada ETF (EWC)

InnoCan Pharma Business Overview & Revenue Model

Company DescriptionInnoCan Pharma (INNO) is a pharmaceutical company engaged in the research, development, and commercialization of innovative therapeutic products. The company operates primarily in the biotechnology and pharmaceutical sectors, focusing on developing novel treatments utilizing its proprietary technology platforms. InnoCan Pharma is known for leveraging cannabinoid science and liposome technology to create therapies aimed at improving health and wellness.
How the Company Makes MoneyInnoCan Pharma generates revenue through the development and commercialization of its proprietary therapeutic products. The company's key revenue streams include licensing agreements, research and development collaborations, and sales of its innovative health products. Significant partnerships with pharmaceutical companies and research institutions play a crucial role in advancing its product pipeline and expanding market reach, contributing to its earnings. By leveraging its unique technological platforms, InnoCan Pharma aims to bring effective treatments to market, thereby driving revenue growth.

InnoCan Pharma Financial Statement Overview

Summary
InnoCan Pharma shows significant revenue growth and improving operational metrics. However, challenges remain in achieving profitability and generating positive cash flows. The balance sheet is stable with low leverage, but consistent net losses could become a concern if not addressed.
Income Statement
45
Neutral
InnoCan Pharma has shown a significant improvement in its financial performance over the years. The TTM (Trailing-Twelve-Months) gross profit margin is robust at 89.61%, indicating efficient cost management. The revenue has grown impressively from 2020 to 2025, highlighting strong market performance. However, the company is still struggling with profitability as indicated by the negative net profit margin of -2.13% in the TTM period, although there's a narrowing loss from previous years. The EBIT margin has turned positive in the TTM period at 1.49%, and the EBITDA margin improved to 4.31%, showing operational improvements.
Balance Sheet
40
Negative
The balance sheet of InnoCan Pharma displays a mixed picture. The company has a low debt-to-equity ratio of 0.28, suggesting conservative leverage. The equity ratio is 43.27%, reflecting a moderate equity base relative to total assets. The return on equity is still negative at -13.86% due to net losses, but this has been improving as losses decrease. While the company has maintained a strong cash position, consistent net losses pose a risk to long-term solvency.
Cash Flow
35
Negative
Cash flow analysis shows improvement in operational cash outflows, with the TTM period reporting a lower negative operating cash flow compared to previous years. The free cash flow is also negative, but the decrease in negative free cash flow indicates progress. The operating cash flow to net income ratio and free cash flow to net income ratio are negative, highlighting the challenges in converting earnings into cash. However, the trend towards improvement is a positive sign.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue28.83M29.44M13.66M2.56M196.00K8.00K
Gross Profit25.50M26.19M11.98M2.11M121.00K3.00K
EBITDA675.00K961.00K-3.77M-3.85M-10.04M-9.90M
Net Income-1.58M-1.83M-4.70M-3.89M-10.06M-15.18M
Balance Sheet
Total Assets11.04M9.26M6.94M6.98M12.57M4.33M
Cash, Cash Equivalents and Short-Term Investments7.25M5.01M3.88M4.95M11.05M2.34M
Total Debt1.40M10.00K33.00K34.00K1.00K38.00K
Total Liabilities4.35M2.24M2.55M751.00K3.56M7.94M
Stockholders Equity4.21M5.17M4.10M6.39M9.05M-3.61M
Cash Flow
Free Cash Flow-469.00K-1.59M-3.95M-6.09M-6.67M-3.69M
Operating Cash Flow-453.00K-1.58M-3.90M-6.07M-6.63M-3.69M
Investing Cash Flow53.00K54.00K-84.00K-31.00K-48.00K0.00
Financing Cash Flow2.41M2.70M2.92M125.00K15.30M4.02M

InnoCan Pharma Technical Analysis

Technical Analysis Sentiment
Positive
Last Price19.45
Price Trends
50DMA
13.71
Positive
100DMA
13.00
Positive
200DMA
12.63
Positive
Market Momentum
MACD
0.48
Negative
RSI
78.14
Negative
STOCH
98.15
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:INNO, the sentiment is Positive. The current price of 19.45 is above the 20-day moving average (MA) of 12.69, above the 50-day MA of 13.71, and above the 200-day MA of 12.63, indicating a bullish trend. The MACD of 0.48 indicates Negative momentum. The RSI at 78.14 is Negative, neither overbought nor oversold. The STOCH value of 98.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:INNO.

InnoCan Pharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
C$89.36M67.401.52%0.03%-17.30%
49
Neutral
C$11.48M-8.49-7.39%10.84%48.57%
46
Neutral
C$6.28M-1.5615.79%
45
Neutral
C$100.85M-15.9467.56%-29.29%12.89%
45
Neutral
$65.23M-34.90%21.46%65.70%
35
Underperform
C$5.29M-0.71-46.59%9.48%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:INNO
InnoCan Pharma
19.45
5.15
36.01%
TSE:MVMD
Mountain Valley MD
0.02
-0.02
-50.00%
TSE:MPH
Medicure
1.10
0.08
7.84%
TSE:MDP
Medexus Pharmaceuticals Inc
2.77
0.19
7.36%
TSE:RVV
Revive Therapeutics
0.02
0.01
100.00%
TSE:BNXT
BioNxt Solutions
0.86
0.61
237.25%

InnoCan Pharma Corporate Events

Delistings and Listing ChangesRegulatory Filings and Compliance
Innocan Pharma Files for U.S. Public Offering and Nasdaq Listing
Positive
Jul 23, 2025

Innocan Pharma has filed a registration statement with the U.S. SEC for a proposed public offering of units in the United States, which includes listing its shares and warrants on the Nasdaq Capital Market. This move is expected to open new opportunities for the company, enhancing its market presence and potentially benefiting stakeholders by expanding its access to capital and increasing visibility in the U.S. market.

Product-Related AnnouncementsExecutive/Board ChangesBusiness Operations and Strategy
Innocan Pharma Reports Promising Study Results and Corporate Changes
Positive
Jul 3, 2025

Innocan Pharma has announced promising results from a study on its liposomal-CBD injection, which showed prolonged release and a favorable safety profile in minipigs. Additionally, the company has undergone a leadership change with the resignation of Executive Chairman Ron Mayron, who will be succeeded temporarily by Iris Bincovich. Innocan also granted RSUs and stock options to its team, reflecting strategic moves to strengthen its workforce and incentivize performance.

Product-Related AnnouncementsBusiness Operations and Strategy
Innocan Pharma’s Synthetic CBD Review to be Presented at PAINWEEK 2025
Positive
Jun 20, 2025

Innocan Pharma announced that its narrative review on long-acting synthetic cannabidiol for chronic pain has been accepted for presentation at the PAINWEEK 2025 conference. The review highlights the potential of Innocan’s LPT-CBD, an injectable liposomal drug product, as a promising non-opioid analgesic alternative, offering prolonged pain relief and addressing opioid dependency. This presentation positions Innocan at the forefront of innovative pain management solutions, potentially impacting its market presence and partnerships.

Product-Related AnnouncementsBusiness Operations and StrategyRegulatory Filings and Compliance
Innocan Pharma Advances Non-Opioid Pain Management with Synthetic CBD
Positive
Jun 13, 2025

Innocan Pharma has announced the publication of a peer-reviewed narrative review in the Cureus journal, highlighting the potential of long-acting synthetic cannabidiol (CBD) for chronic pain management. This development aligns with the FDA’s emphasis on non-addictive pain therapies and positions Innocan’s LPT-CBD platform as a promising alternative to opioids, with regulatory submissions underway to advance it into human clinical trials.

Business Operations and StrategyFinancial Disclosures
Innocan Pharma Reports Strong Q1 2025 Results and Advances CBD Technology
Positive
May 28, 2025

Innocan Pharma reported a strong financial performance in the first quarter of 2025, with a 15% increase in revenue to $7.8 million and a shift from an operating loss to a profit. The company is expanding its intellectual property coverage in Asia and advancing its LPT-CBD technology, which has received positive feedback from the FDA. Innocan’s efforts in both human and veterinary markets, particularly in chronic pain management, are positioning it for continued growth and innovation.

Product-Related AnnouncementsBusiness Operations and Strategy
Innocan Pharma Secures First Mexican Patent for Cannabis-Based Pain Relief
Positive
May 6, 2025

Innocan Pharma has been granted its first patent in Mexico for a proprietary cannabis-based topical pain relief formulation, marking a significant milestone in its intellectual property portfolio. This approval positions the company for strategic entry into Latin American markets, complementing existing patents in the United States, Russia, and Ukraine, and underscores its leadership in cannabidiol-based wellness innovation.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 25, 2025